bioMérieux Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Pierre Boulud
Chief executive officer
€1.8m
Total compensation
| CEO salary percentage | 28.2% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 4.7yrs |
| Board average tenure | 11.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | €386m |
| Mar 31 2023 | n/a | n/a | €419m |
| Dec 31 2022 | €2m | €510k | €452m |
| Sep 30 2022 | n/a | n/a | €502m |
| Jun 30 2022 | n/a | n/a | €552m |
| Mar 31 2022 | n/a | n/a | €577m |
| Dec 31 2021 | €2m | €510k | €601m |
| Sep 30 2021 | n/a | n/a | €555m |
| Jun 30 2021 | n/a | n/a | €509m |
| Mar 31 2021 | n/a | n/a | €457m |
| Dec 31 2020 | €1m | €497k | €404m |
Compensation vs Market: Pierre's total compensation ($USD1.94M) is below average for companies of similar size in the US market ($USD12.18M).
Compensation vs Earnings: Pierre's compensation has been consistent with company performance over the past year.
CEO
Pierre Boulud (52 yo)
less than a year
Tenure
€1,806,852
Compensation
Mr. Pierre Boulud is Chief Executive Officer of bioMérieux S.A. from 2023. He served as Chief Operating Officer of Clinical Operations at BioMérieux S.A. until 2023 and served as its Chief Operating Office...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 19.4yrs | €1.38m | 0.000050% $ 5.9k | |
| Chief Executive Officer | less than a year | €1.81m | no data | |
| Head of CSR | 3.7yrs | €21.99k | 0.0025% $ 296.0k | |
| Executive VP of Purchasing and Information Systems & CFO | 5.5yrs | no data | no data | |
| Investor Relations | no data | no data | no data | |
| Executive Vice President of Legal Affairs & Integrity | less than a year | no data | no data | |
| Executive Vice President of Human Resources | 4.7yrs | no data | no data | |
| Executive Vice President of R&D | 5.5yrs | no data | no data | |
| Executive VP & Chief Medical Officer | 10.9yrs | no data | no data | |
| Executive Vice President of Global Quality | 5.5yrs | no data | no data | |
| Executive Vice President of Industrial Microbiology | 5.5yrs | no data | no data | |
| Executive Vice President of Clinical Operations | less than a year | no data | no data |
4.7yrs
Average Tenure
49yo
Average Age
Experienced Management: BMXX.Y's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 19.4yrs | €1.38m | 0.000050% $ 5.9k | |
| Founding Chairman | 6.1yrs | no data | no data | |
| Non-Independent Director | 17yrs | €46.00k | 0.051% $ 6.1m | |
| Non-Independent Director | 13.3yrs | €61.00k | 0.000030% $ 3.6k | |
| Independent Director | 11.3yrs | €61.00k | 0.00013% $ 15.5k | |
| Independent Director | 11.3yrs | €46.00k | 0.000050% $ 5.9k | |
| Independent Director | 6.3yrs | €41.00k | 0.000030% $ 3.6k | |
| Independent Director | 6.1yrs | €40.00k | 0.00015% $ 17.8k | |
| Director | 1.3yrs | €13.03k | no data |
11.3yrs
Average Tenure
59yo
Average Age
Experienced Board: BMXX.Y's board of directors are seasoned and experienced ( 11.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/05 23:36 |
| End of Day Share Price | 2023/06/09 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
bioMérieux S.A. is covered by 34 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Armelle Moulin | AlphaValue |
| Gaurav Jain | Barclays |
| Samuel England | Berenberg |